NasdaqGS:REGNBiotechs
Regeneron Faces Neurology Leadership Shift As Investors Weigh Pipeline Execution
Regeneron Pharmaceuticals (NasdaqGS:REGN) has seen the departure of Dr. Wolfgang Liedtke, its Chair of Neurology.
Dr. Liedtke is joining Anavex Life Sciences in a global executive role.
His exit follows a tenure focused on integrating discovery into late stage neurology clinical trials at Regeneron.
For investors watching NasdaqGS:REGN, this move comes in the context of a biopharma company with a significant focus on neurology research and clinical development. Leadership shifts in research...